Panagiotis A. Konstantinopoulos, MD, PhD
PARP inhibitors have made a splash in the ovarian cancer landscape, particularly for those with BRCA
-mutated tumors. The benefit of these agents as monotherapy has been limited in the platinum-resistant/refractory settings, but there may be hope in combination with immunotherapy, according to Panagiotis A. Konstantinopoulos, MD, PhD.
, Konstantinopoulos, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, and lead TOPACIO/KEYNOTE-162 investigator, discussed the findings of the study and the future for PARP inhibitor combinations and immunotherapy overall in ovarian cancer.
OncLive: Please provide some background information on this study.
: Platinum-resistant/refractory ovarian cancer is an important unmet need, as there are very limited treatment options for these patients. Bevacizumab (Avastin) in combination with chemotherapy is currently FDA approved based on the AURELIA study, which was done in patients with up to 2 prior lines of chemotherapy. In patients with platinum-resistant disease, PARP inhibitors have shown very limited activity as monotherapy. In patients with BRCA
-mutated platinum-resistant disease, the ORR is 25% to 30%, which has led to their FDA approval. However, outside that setting, in BRCA
wild-type, platinum-resistant disease, the ORR is only 5%. In BRCA
-mutated platinum-refractory disease, the ORR is 0% to 14%.
... to read the full story